Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (121-130 of 211) with videos related to

Pageof 22
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Blood|January 24, 2012
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantationMelinda A Biernacki, Yu-tzu Tai, Guang Lan Zhang, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Nature Communications|February 9, 2021
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myelomaMehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, et al.
Oncogene|August 29, 2024
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Pageof 22

Showing results (121-130 of 211) with videos related to

Sort By:
Pageof 22
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2012
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myelomaClaire Fabre, Naoya Mimura, Kathryn Bobb, et al.
Blood|January 24, 2012
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantationMelinda A Biernacki, Yu-tzu Tai, Guang Lan Zhang, et al.
Blood|May 7, 2009
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaMariateresa Fulciniti, Pierfrancesco Tassone, Teru Hideshima, et al.
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Nature Communications|February 9, 2021
Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myelomaMehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, et al.
Oncogene|August 29, 2024
Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Oncogene|October 14, 2004
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cellsTeru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Cancer Research|December 17, 2005
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsYu-Tzu Tai, Xian-Feng Li, Laurence Catley, et al.
Pageof 22